PERVALUE CAPITAL’s Post

𝗜𝗻𝘀𝗶𝗱𝗲 𝗔𝗹𝘁𝗼𝘀 𝗟𝗮𝗯𝘀: 𝗛𝗼𝘄 $𝟯 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝗥&𝗗 𝗳𝗿𝗼𝗺 𝗩𝗖 𝗶𝘀 𝗙𝘂𝗲𝗹𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 In the fast-evolving field of biotechnology, Altos Labs stands out as a true game-changer. Supported by visionary venture capital, Altos is spearheading a new era in health through pioneering research into cell rejuvenation with the goal of reversing disease. Their mission transcends traditional approaches to aging, aiming for a radical shift in how we understand and treat the cellular processes that drive aging and disease. 𝗧𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗕𝗲𝗵𝗶𝗻𝗱 𝘁𝗵𝗲 𝗩𝗶𝘀𝗶𝗼𝗻 Altos Labs builds on the 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝘄𝗼𝗿𝗸 𝗼𝗳 𝗦𝗵𝗶𝗻𝘆𝗮 𝗬𝗮𝗺𝗮𝗻𝗮𝗸𝗮, whose discovery in 2006 showed that cells can be reprogrammed into a youthful, embryonic-like state. 𝗔𝗹𝘁𝗼𝘀 𝗙𝗼𝘂𝗻𝗱𝗶𝗻𝗴 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝗝𝘂𝗮𝗻 𝗖𝗮𝗿𝗹𝗼𝘀 𝗜𝘇𝗽𝗶𝘀𝘂𝗮 𝗕𝗲𝗹𝗺𝗼𝗻𝘁𝗲 expanded this concept in 2016 by demonstrating the possibility of “𝗽𝗮𝗿𝘁𝗶𝗮𝗹” 𝗿𝗲𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗶𝗻𝗴. This method allows cells to become more resilient to stress and disease without losing their identity—paving the way for cellular rejuvenation that could transform how we treat age-related diseases and conditions. 𝗔𝗜-𝗗𝗿𝗶𝘃𝗲𝗻 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 Altos Labs’ progress is powered not only by 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗯𝘂𝘁 𝗮𝗹𝘀𝗼 𝗯𝘆 𝗮𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲. AI accelerates discovery by modeling cellular processes, predicting outcomes, and optimizing reprogramming techniques. This 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗜 into the research process allows Altos to expedite the development of applications that could reshape the future of regenerative medicine. 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗣𝗮𝘁𝗵 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 As of the latest available data, Altos Labs has raised over $𝟯 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝘃𝗲𝗻𝘁𝘂𝗿𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝗳𝘂𝗻𝗱𝗶𝗻𝗴, 𝗽𝗿𝗶𝗺𝗮𝗿𝗶𝗹𝘆 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗶𝘁𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 efforts in cellular rejuvenation and anti-aging technologies. This significant investment demonstrates the high level of confidence that venture capitalists have in the company's potential to disrupt the healthcare and biotech industries. Investors include notable names such as 𝗝𝗲𝗳𝗳 𝗕𝗲𝘇𝗼𝘀 𝗮𝗻𝗱 𝗬𝘂𝗿𝗶 𝗠𝗶𝗹𝗻𝗲𝗿, further underscoring the magnitude of the mission Altos Labs has embarked on. 𝗔 𝗙𝘂𝘁𝘂𝗿𝗲 𝗕𝗲𝘆𝗼𝗻𝗱 𝗔𝗴𝗶𝗻𝗴 If successful, Altos Labs could revolutionize medicine, making the reversal of diseases linked to aging a reality. Their work holds the promise of a future where healthspan—how long we remain healthy—is dramatically extended. Altos Labs is not just imagining a world free from the limitations of aging; they are actively building it. #Innovation #entrepreneurship #leadership #Technology

Research Institution Proof of Concept, Startup Accelerator, and Venture Fund Gap Fund and Accelerator Programs (GAP for short) #innovation #university #research #gapfunding #proofofconcept #startup #accelerator #venture #commercialization

This Biotech Startup Raised $17 Million To Keep You Young Forever Integrated Biosciences—a biotech company discovering and developing drugs to cure age-associated illnesses like cancer, Alzheimer's and diabetes-announced it’s raised some $17 million in seed funding led by Sutter Hill Ventures, with participation from Illumina Venture Labs, Mission BioCapital and more. Wong explains the startup is trying to “drug aging itself as opposed to any specific disease,” which means they aren’t finding cures for a particular illness, but instead trying to create therapies that target the cells in our bodies that go awry as we age. How does he plan to pull off the eternal challenge? AI of course. Wong is training machine learning to identify the tiniest of molecules inside aging cells, understand what’s happening with them, and then create drugs that will target and restore those molecules to keep us, biologically, young. Wong has previously had luck with this tech-first approach: He was amongst the researchers at Massachusetts Institute of Technology who found an entirely new class of antibiotics using AI. Can it work? Partners like Illumina, the biotech giant with a $22 billion market cap, think so. Illumina announced a collaboration with Integrated Biosciences earlier this year, to provide scientific support in addition to the cash investment. Wong declined to publicly disclose other partners’ names, but they go as far as pairing up with skincare labs to create anti-aging remedies. The collaborations helped Integrated start generating revenue, which is currently at around $1 million this year. Both Wong and his cofounder Max WiIlson come from a science background, holding PhDs in biology and physics. But they say the business proposition here is just as big as the moral cause. “The largest growing market in the world right now is aging people—the baby boomers are now getting into their retirement, and they also are looking to continue leading healthy, happy lives,” Wilson said. “So as a business proposition, it's excellent, and there's a huge amount of suffering that we can attack and alleviate by going after these diseases.” $17 million doesn’t seem like nearly enough to take on such an ambitious goal when comparing Integrated to competing labs like Altos, which also emerged in 2022 but with $3 billion in funding—backed by Jeff Bezos. But Wong and Wilson say they’re staying in the race. Altos doesn’t have FDA-approved drugs yet either, and Integrated, with only five full-time employees, has learned how to keep it lean. The cofounders say they’re confident the new cash will help bring their drugs to the clinical trial stage. https://lnkd.in/eVYjfc-M

🏥 Exciting news for CARETECH HUMAN! Housed at Center for Life Science Ventures Cornell University #incubator, the startup recently acquired a $175,000 investment to manufacture devices that analyze toilet water for urology diseases – such as diabetes ⚕. CEO Dan Matsui, PhD notes "There's been a gap in home urology monitoring—our device fills that void." CARETECH HUMAN seeks to enhance the patient care experience through preventative detection, which may potentially reduce long term healthcare costs 📉. The investment is fueled by 🚀 Launch NY's mission to support "seed stage capital into these Upstate New York startup companies can create market-leading products competitive not only locally, but nationally”, according to Marnie LaVigne, Ph.D. Through Launch NY's #InvestLocal financing programs, 300+ accredited investors use both nonprofit and for-profit funds to back Upstate NY startups. #CaretechHuman #LaunchNY #HealthTech #Innovation #StartupInvestment #lifescience #ventures #medtech #urology #diabetes https://lnkd.in/e7vRjN72

🚀 Startup Matter Bio raises $7M in seed funding to revolutionise human longevity! 🚀 Matter Bio, a promising human longevity-focused startup, has successfully raised $7 million in seed funding. This funding round was led by Lifespan Vision Ventures, with participation from quadraScope Ventures and other unnamed investors. The Brooklyn-based company also received grant support from the The National Institutes of Health (NIH). 🎉💰 Funding Details: Lead Investor: Lifespan Vision Ventures Participants: quadraScope Ventures and unnamed investors Support: Grant from the National Institutes of Health (NIH) About Matter Bio: Matter Bio serves as a holding company for three innovative biotechs: - Mutagentech: Investigating the role of somatic mutations and structural variants in disease 🧬 - Loki Therapeutics: A clinical-stage firm developing cancer immunotherapies 💉 - Spellcheck Bio: Focused on precision DNA-editing technology 🧩 Founding Team: Among the cofounders are: - Chris Bradley: CEO - Sam Sharifi, PhD - George Church: Harvard University scientist and Spellcheck Bio Cofounder - Jan Vijg and Alex Maslov: Mutagentech Cofounders - claudia Gravekamp: Loki Therapeutics Cofounder and CSO, researchers at Albert Einstein College of Medicine Technological Approach: Matter Bio aims to develop a therapeutic approach that detects and identifies mutations, structural variations, epigenetic drift, and other DNA damages contributing to aging. This approach includes correcting these damages and replacing them with original genetic information while eliminating cells that are too damaged to be repaired. 🧬🔄 Next Steps: The seed money will be used to continue research and initiate a Phase I/IIa clinical trial in solid cancer. "Genomic integrity is a cornerstone of longevity and health span extension," said George Church. "Matter Bio is pioneering a crucial approach in the fight against aging by focusing on the preservation of our genetic blueprint." This funding marks a significant step forward in the quest for extending human health span and longevity. 🌟👏 #MatterBio #Longevity #Biotech #GenomicIntegrity #HealthSpan #PrecisionMedicine #CancerResearch #Startups #Funding #Innovation #Healthcare #FutureOfMedicine

#BiomedTech #Startups #Funding Biotech Funding Surge: Top Startups Raise $2.9B in Q1 2024” -Record Funding: The top 20 healthcare-focused biotech companies collectively raised $2.9 billion in Q1 2024, marking a 161% increase compared to the previous year. -Market Confidence: Investors are making more confident bets on the market viability of promising healthcare biotechnology firms. -Focus Areas: Funding recipients include companies specializing in precision oncology, AI-driven drug discovery, cell and gene therapies, and novel approaches to treating autoimmune disorders. Alumis Alumis (formerly Esker Therapeutics) secured $529M in cumulative funding, focusing on precision immunology and targeted treatments for autoimmune diseases. Freenome Freenome, a leader in early cancer detection, raised $1.35B in total funding for its multiomics screening platform. #BiotechFunding #HealthcareInnovation #PrecisionMedicine #HealthTech #LifeSciences #InvestmentNews #HealthcareStartups #InnovationFunding Ahmed-digital doc- Otokiti MD, MBA, MPH Alister Martin Philippe GERWILL Umer Khan M. Karim Beguir Harvey Castro, MD, MBA. Gabriella Marcelja

Here's the hard truth: Most university research never sees the light of day. Shocking, right? As someone who has worked in research, it's frustrating to see amazing breakthroughs that never make it to the market. But... There's a new trend emerging. University research turned into startups. These companies bridge the gap between research and commercialization, allowing researchers to see their life-changing discoveries in action. For example: - Vaxxas, a needle-free vaccine delivery system - Inivata, a liquid biopsy for cancer detection - Bioelektra Group, a non-invasive wound treatment device These companies prove that research and entrepreneurship can go hand in hand. So if you're a researcher, consider starting a company. And if you're an investor, keep an eye on university startups. Because there's no telling where the next revolutionary product will come from.

Meet our speakers for the 'Navigating Grant Funding for Startups in Europe' webinar, taking place on Zoom this Thursday! 👇🏽 Marina Rigau, PhD is a CEO and co-founder of MiMARK Diagnostics, S.L. Marina has over 15 years of experience in biomedical research across academia and the biotech sector. She has dedicated her scientific career to translational research in cancer diagnostics using biological fluids, contributing to over 25 peer-reviewed publications and holding two patents. MiMARK Diagnostics SL is a pioneering biotechnology startup dedicated to advancing women’s health through groundbreaking in vitro diagnostic solutions. Located in Barcelona, MiMARK specializes in the development of diagnostic tests for gynecological malignancies, with a particular focus on endometrial cancer. Their innovative approach uses gynecological fluid as a liquid biopsy medium, aiming to revolutionize the diagnosis and management of gynecological cancers. MiMARKis one of the 11 companies that joined the BCN Health Booster accelerator in 2021, promoted by the Barcelona Science Park, Barcelona City Council, Barcelona Activa and Biocat. To date, the company has received a total of €2.4 million in public funding. If you are an aspiring entrepreneur or a founder in the femtech, health tech, or biotech industry looking for funding opportunities, then join us for this virtual event where you'll gain valuable insights into securing grants and hear directly from successful startup founders who have navigated the journey themselves. Register via the link below 👇🏽 https://buff.ly/4ex0NlB #femalefounders #womenintech #womeninbusiness #funding #fundraising #investment #femaleinvestors #venturecapital #vc #venturecapital #angelinvestors #startups #innovation #diversity #inclusion #diversityandinclusion #healthtech #femtech #digitalhealth #biotech #medtech #grants #grantfunding #eufunding #eicfunding

Thinking about starting a biotech company?💡 Building a biotech startup is a unique challenge that requires navigating scientific validation, regulatory hurdles, and securing funding. Founders must choose the right focus, attract talent, and understand the importance of intellectual property. But the potential rewards are immense for those who can persevere through the complexities.✨ Labiotech reached out to several biotech founders to give practical advice to aspiring entrepreneurs. 🤝 Discover what they learned from their experience! ⬇️ https://lnkd.in/dCuKmuhB #biotechstartup #entrepreneurship #startupchallenges #scientificinnovation #biotechjourney #startupadvice #biotechsuccess Alexander Shneider | CureLab Oncology | Xavier Duportet | Eligo Bioscience | Mati Gill | AION Labs | Jennifer Good | Trevi Therapeutics, Inc. | Paul Jaminet | Angiex Inc.

🚀DEALFLASH - WEEK 45🚀 An overview of early-stage deals in European bio-, health- and life sciences. seed. ⚕️uPATCH Scope: uPATCH aims to accelerate the transition of microneedles from a research environment into real-world, lifesaving solutions. Investors: Shaping Impact Group Ticket size: n/a 📊OptimallyMe Scope: OptimallyMe goal is to keep you connected to, educated about, and involved in your health. Investors: The Players Fund Ticket size: n/a 👨⚕️OPCI Limited Scope: OPCI is a MedTech company that predicts patients potential post-operative problems to help clinicians make decisions. Investors: n/a Ticket size: GBP 600k 🧬Phlox Therapeutics Scope: Phlox Therapeutics specializes in the development of gene therapy to alleviate and cure cardiomyopathies. Investors: UvA - Amsterdam UMC - HvA Ventures Holding BV, FIRST fund, ROM Utrecht Region, Utrecht Holdings Ticket size: EUR 1.9 MM 🌊SeaO2 Scope: SeaO2 is an ocean carbon removal startup that offers scalable carbon dioxide removal technology at the giga-ton level. Investors: CarbonFix, DOEN Participaties B.V., Future Tech Ventures, NVNO & angel investors Ticket size: EUR 2 MM 🦠iFAST Diagnostics Scope: iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. Investors: E Ink Corporation, Kadmos Capital Ltd, KHP Ventures, OKG Capital, QantX, Raw Ventures, UK Innovation & Science Seed Fund Ticket size: EUR 5.9 MM 🤖R.grid Scope: R.grid has built machine learning-based software for medical research. Investors: Ada Ventures, Arve Capital, Arāya Ventures, Ascension Ventures, Atomico, Fuel Ventures 🚀, Inclusive Ventures Lab, Plug and Play Ticket size: USD 6.5 MM series a. 📈Yazen Health Scope: Yazen provides digital weight loss solutions through personalized coaching and support. Investors: Aggregate Media, Almaz Capital, Evli Growth Partners, Helsana HealthInvest, Luminar Ventures, yabeo Ticket size: EUR 19.5 MM 📱TCC GmbH Scope: Telehealth Competence Center develops digital telemedicine solutions for healthcare sectors. Investors: Angel investors Ticket size: EUR 20 MM Looking for easier and more successful fundraising in bio-, health- and life sciences? Contact us at hello@ensemblate.com. #innovation #lifesciences #fundraising #venturecapital